logo-loader
viewSeelos Therapeutics

Seelos Therapeutics' drug-therapy pipeline moves forward as it preps trials for Ketamine-based PTSD treatment

Preparations are underway to initiate a Phase 1 study of intranasal racemic ketamine (SLS-002) to further evaluate interactions in patients with post-traumatic stress disorder

the brain
First patient with Sanfilippo Syndrome expected to be dosed with Trehalose (SLS-005) in Phase 2b/3 trial in third quarter of 2019

Seelos Therapeutics Inc (NASDAQ:SEEL), a clinical-stage biopharmaceutical company, said Tuesday that its drug-therapy pipeline is moving forward on several fronts.

The New York-based company said preparations are underway to initiate a Phase 1 study in the third quarter of intranasal racemic ketamine (SLS-002) to further evaluate the pharmacokinetics, pharmacodynamics, and drug-to-drug interactions in patients with post-traumatic stress disorder who are at imminent risk of suicide.

READ: Seelos Therapeutics’ blockbuster ketamine drug could be the next wonder antidepressant

Seelos also said the first patient with Sanfilippo Syndrome is expected to be dosed with Trehalose (SLS-005) in an FDA/EMA open-label Phase 2b/3 trial in the third quarter of 2019.

Sanfilippo Syndrome is a rare disease in which the body doesn’t have certain enzymes to break down long chains of sugar molecules and can be fatal in some cases. Children with the syndrome develop a developmental disability and seizures. Patients usually live into adolescence or early adulthood.

Lastly, the company said it has initiated in the current quarter a peptide-based approach targeting the NACore (nonamyloid component core) in Parkinson’s disease in a proof-of-concept, in-vivo delivery of SLS-007 in a transgenic mice model.

Seelos’ stock recently traded down 1.8% to $2.77 a share.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Seelos Therapeutics

Price: 0.8614 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $23.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read